Efficacy and Safety of Switching From Sitagliptin to Liraglutide in Subjects With Type 2 Diabetes Not Achieving Adequate Glycaemic Control on Sitagliptin and Metformin
Phase of Trial: Phase IV
Latest Information Update: 25 Jan 2019
Price : $35 *
At a glance
- Drugs Liraglutide (Primary) ; Metformin; Sitagliptin
- Indications Type 2 diabetes mellitus
- Focus Therapeutic Use
- Acronyms LIRA-SWITCH
- Sponsors Novo Nordisk
- 31 Aug 2018 Biomarkers information updated
- 16 Sep 2016 Post hoc analysis of composite endpoints (n=407) presented at the 52nd Annual Meeting of the European Association for the Study of Diabetes.
- 04 Apr 2016 Results presented at The 98th Annual Meeting of the Endocrine Society.